Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan-Mar;12(1):44-52.
doi: 10.4103/jovr.jovr_254_15.

Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection

Fariba Ghassemi  1 , Sohrab Afshari Mirak  2 , Hormoz Chams  1 , Siamak Sabour  3 , Mehdi Nilli Ahmadabadi  1 , Fereidoun Davatchi  4 , Farhad Shahram  4
Affiliations

Characteristics of Macular Edema in Behcet Disease after Intravitreal Bevacizumab Injection

Fariba Ghassemi et al. J Ophthalmic Vis Res. 2017 Jan-Mar.

Abstract

Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease.

Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist.

Results: Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness.

Conclusion: During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME.

Keywords: Behcet's Disease; Intravitreal Bevacizumab; Macular Edema; Uveitis.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Changes in visual acuity (best corrected visual acuity [BCVA]; LogMAR) and central macular thickness (CMT; μm) after intravitreal bevacizumab injection in cases (group 1) and controls (group 2) during the 6-month follow-up period.
Figure 2
Figure 2
Changes in best corrected visual acuity (BCVA; LogMAR) and central macular thickness (CMT; μm) after intravitreal bevacizumab injection in cases (group 1) and controls (group 2) after removing the outliers (three refractory cases) during the 6-month follow-up period.
Figure 3
Figure 3
Optical coherence tomography (OCT) changes in the intravitreal bevacizumab (IVB)-injected eyes in five patients with Behcet's disease. The OCT changes in thickness after IVB injection at months 0, 1, 3, and 6 are shown consecutively.
See this image and copyright information in PMC

References

    1. Chajek T, Fainaru M. Behcet's disease. Report of 41 cases and a review of the literature. Medicine. 1975;54:179–196. - PubMed
    1. Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A. Vascular involvement in Behcet's disease: 8-year audit. World J Surg. 1994;18:948–953. - PubMed
    1. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behcet's disease: An analysis of 2147 patients. Yonsei Med J. 1997;38:423–427. - PubMed
    1. Longo DL. Harrison's Principles of Internal Medicine. 18th ed. New York: McGraw-Hill; 2012.
    1. Pandrea A, Rudinskaya A, Klein B, Krebs T. What does it take to diagnose Behçet disease? J Clin Rheumatol. 2007;13:31–34. - PubMed